The rise in cases of Crohn’s Disease stimulates the research and development of the drug, as it is likely to provide an appropriate environment for newer products to be profitable. Several major pharma and biotech giants such as Takeda Pharmaceutical, Janssen Pharmaceuticals, UCB, Biogen, AbbVie, AstraZeneca, Tillotts Pharma (Zeria Pharmaceutical), Gilead Sciences and Galapagos NV, Boehringer Ingelheim, Celgene (Bristol Myers Squibb), Eli Lilly and Company, RedHill Biopharma, Arena Pharmaceuticals, Mesoblast and others are developing therapies for the Crohn’s Disease.
DelveInsight’s “Crohn’s Disease Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Crohn’s Disease market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The report covers emerging Crohn’s Disease drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Crohn’s Disease treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Crohn’s Disease: An Overview
Inflammatory bowel disease (IBD) is an idiopathic disease caused by a dysregulated immune response to host intestinal microflora. It is a group of inflammatory conditions of the colon and small intestine. In IBD, the immune system responds incorrectly to environmental triggers, which causes inflammation of the gastrointestinal tract.
The two major types of IBD are ulcerative colitis (UC), which is inflammation and sores (ulcers) along the superficial lining of the large intestine (colon) and rectum, and Crohn’s disease (CD), which involves inflammation of the lining of the digestive tract and can often involve the deeper layers of the digestive tract. There are different types of Crohn’s Disease, each affecting different parts of the digestive tract, including ileocolitis, ileitis, gastroduodenal Crohn’s disease, jejunoileitis, and Crohn’s colitis. The causes of Crohn’s Disease are not yet well understood, but genetic, immune response and environmental factors are suspected to contribute to Crohn’s Disease development.
Crohn’s Disease is typically more severe than ulcerative colitis, but is slightly less common. The disease can occur at any age, but Crohn’s Disease is most often diagnosed in adolescents and adults between the ages of 20 and 30.
Crohn’s Disease Market Key Facts
-
In 2021, among the EU-5 countries, Germany had the highest Crohn’s Disease market share, followed by UK and Italy.
-
Spain holds the smallest share of the 7MM Crohn’s Disease market, with a market size of USD 167 million in 2021.
-
The total prevalent population of Crohn’s Disease in 7MM was estimated to be 1,613,000+ cases in 2021, which is expected to increase by 2032.
-
The US accounted for the highest prevalent population of Crohn’s Disease among 7MM, with 832,000+ cases in 2021.
-
The estimates suggest a higher diagnosed prevalence of Crohn’s Disease in the United States, with 595,000+ diagnosed cases in 2021.
-
Among the European countries, the total prevalent population of Crohn’s Disease was highest in Germany with 227,000+ cases, followed by the UK with 147,000+ cases in 2021. Spain reported the least number of cases among EU-5 with 74,000+ cases in 2021.
-
In June 2022, SKYRIZI (risankizumab) was approved by the US FDA as the first and only specific interleukin-23 (IL-23) inhibitor for the treatment of adults with moderately to severely active Crohn’s disease (CD).
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Crohn’s Disease pipeline therapies. It also thoroughly assesses the Crohn’s Disease market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete detail of the market trend for each marketed Crohn’s Disease drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Crohn’s Disease Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted Crohn’s Disease epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Crohn’s Disease epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders.
The Report Covers the Crohn’s Disease Epidemiology, Segmented as –
-
Total Prevalent Cases of Crohn’s Disease in the 7MM (2019–2032)
-
Age-specific Diagnosed Prevalent Cases of Crohn’s Disease in the 7MM (2019–2032)
-
Severity-specific Diagnosed Prevalent Cases of Crohn’s Disease in the 7MM (2019–2032)
-
Total Diagnosed Prevalent Cases of Crohn’s Disease in the 7MM (2019–2032)
Crohn’s Disease Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Crohn’s Disease market or expected to be launched during the study period. The analysis covers the Crohn’s Disease market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Crohn’s Disease drugs based on their sale and market share.
The report also covers the Crohn’s Disease pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Crohn’s Disease companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Crohn’s Disease Market Will Evolve and Grow by 2032 @
https://www.delveinsight.com/sample-request/crohns-disease-cd-market
Crohn’s Disease Therapeutics Analysis
Several major pharma and biotech companies are developing therapies for Crohn’s Disease. Currently, Janseen is leading the therapeutics market with its Crohn’s Disease drug candidates in the most advanced stage of clinical development.
Crohn’s Disease Companies in the Therapeutics Market Include:
4D Pharma, Abbvie, Abivax, Aclaris Therapeutics, Active Biotech, Aibios Co Ltd, Akeso Biopharma, Alfasigma, Algernon Pharmaceticals, Alpha Cancer Technologies, Amgen, Arena Pharmaceuticals, Artelo Biosciences, Assembly Biosciences, AstraZeneca, Athos Therapeutics, Atlantic Bio Sci, Atlantic Healthcare, Avexegen Therapeutics, Avobis Bio LLC, Bristol-Myers Squibb, Celgene, Celularity, Cerecor, ChemoCentryx, Chong Kun Dang Pharmaceutical Corp, Cloud Pharmaceuticals, Commence Bio Inc, Curacle, Cytocom, Denali Therapeutics, Draconis Pharma, Educell doo, Eisai, Eli Lilly and Company, Enzo Biochem Inc., Exeliom Biosciences SAS, Fast Forward Pharmaceuticals, Finch Therapeutics, Gilead Sciences, GlaxoSmithKline, HAV Vaccines Ltd, Hoffmann-La Roche, Iltoo Pharma, Immunic, Innovative Pharmacological Research (IPHAR) Co Ltd, Innovimmune Biotherapeutics, Intract Pharma Ltd, Janssen, JHL Biotech, Kang Stem Biotech, Koutif Therapeutics, Landos Biopharma, MakScientific, Mesoblast, Metacrine, Mitsubishi Tanabe Pharma Corporation, Morphic Therapeutic, Navidea Biopharmaceuticals, Neuclone, Orchard Therapeutics, Origo Biopharma, Pfizer, PlantPraxis, Priothera, Protagonist Therapeutics, Provention Bio, Qu Biologics, RedHill Biopharma, Reistone Biopharma Company Limited, Roche, SLA Pharma, Soligenix, Stero Biotechs, Suzhou Connect Biopharmaceuticals, Synedgen, Synlogic, TaiwanJ Pharmaceuticals, Takeda Pharmaceuticals, Temisis Therapeutics, Theravance Biopharma, Thetis Pharmaceuticals, Tiziana Life Sciences, Tract Therapeutics, Trio medicines, VHsquared Ltd., Winston Pharmaceuticals, Xbrane, and many others.
Emerging and Marketed Crohn’s Disease Therapies Covered in the Report Include:
-
Alofisel (Darvadstrocel/Cx601): Takeda Pharmaceuticals
-
Brazikumab (MEDI 2070): AstraZeneca
-
Budesonide (Entocort/Zentacort)/ Budesonide-Multi-Matrix System (MMX): AstraZeneca/Tillotts Pharma
-
Cimzia (Certolizumab-pegol): UCB
-
Entyvio (Vedolizumab): Takeda Pharmaceutical
-
Etrasimod (APD334): Arena Pharmaceuticals
-
Guselkumab: Janssen
-
Humira (Adalimumab): AbbVie
-
Jyselica (Filgotinib): Gilead Sciences/ Galapagos NV
-
Mirikizumab (LY3074828): Eilly Lilly and Company
-
Remicade (Infliximab): Janssen Biotech
-
RHB-104: RedHill Biopharma
-
Rinvoq (Upadacitinib; ABT494): AbbVie
-
Ryoncil (Remestemcel-l): Mesoblast
-
Skyrizi (risankizumab): Abbvie
-
Stelara (Ustekinumab): Janssen Pharmaceuticals
-
Tremfya (Guselkumab): Janssen (Johnson and Johnson)
-
Tysabri (Natalizumab): Biogen
-
Zeposia (Ozanimod; RPC1063): Celgene (Bristol Myers Squibb)
And many more
The Report Covers the In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @
https://www.delveinsight.com/sample-request/crohns-disease-cd-market
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Crohn’s Disease Competitive Intelligence Analysis
4. Crohn’s Disease Market Overview at a Glance
5. Crohn’s Disease Disease Background and Overview
6. Crohn’s Disease Patient Journey
7. Crohn’s Disease Patient Population and Epidemiology Trends (In the US, EU5, and Japan)
8. Crohn’s Disease Treatment Algorithm, Current Treatment, and Medical Practices
9. Crohn’s Disease Unmet Needs
10. Key Endpoints of Crohn’s Disease Treatment
11. Crohn’s Disease Marketed Therapies
12. Crohn’s Disease Emerging Drugs and Latest Therapeutic Advances
13. Crohn’s Disease Seven Major Market Analysis
14. Attribute Analysis
15. Crohn’s Disease Market Outlook (In US, EU5, and Japan)
16. Crohn’s Disease Companies Active in the Market
17. Crohn’s Disease Access and Reimbursement Overview
18. KOL Views on the Crohn’s Disease Market
19. Crohn’s Disease Market Drivers
20. Crohn’s Disease Market Barriers
21. Appendix
22. DelveInsight Capabilities
23. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download the Sample PDF to Learn More About the Key Offerings of the Report @
https://www.delveinsight.com/sample-request/crohns-disease-cd-market
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Unlock growth opportunities in the ever-evolving medical devices market with our data-driven insights. Stay ahead of industry shifts and make informed decisions to thrive in this dynamic landscape, at: Global Medical Devices Market
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/oncology